NCT06241235View on ClinicalTrials.gov

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 27, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Cervical Carcinoma
Interventions
DRUG

ZG005 Powder for Injection

ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion, intravenous infusion(IV), once every 3 weeks (Q3W). ZG005 for dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.

DRUG

Paclitaxel

IV infusion

BIOLOGICAL

Bevacizumab

IV infusion

DRUG

Cisplatin

IV infusion

DRUG

Carboplatin

IV infusion

Trial Locations (1)

310022

RECRUITING

Zhejiang Cancer Hospital, Zhejiang

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY